Quinten Health developed PharmIA on the job at the point of care, in partnership with two French hospitals to help personalizing patient care by integrating patient monitoring data and optimizing the use of pharmaceutical products.
PharmIA is a software powered by AI and dedicated to helping hospital pharmacists focus their time on the most critical patients and prescriptions and ease their analysis by providing contextualized information and alerts.
In Europe, approximately 5% of hospitalized patients experience adverse drug effects during hospitalization, leading to considerable mortality and morbidity. Yet only 13% of the adverse drug reactions are not preventable. However, hospital pharmacists must analyze hundreds of prescriptions very quickly and determine the potential risks, without prior information on the patients most likely to be at risk, while the existing software solutions to detect drug interactions and contra-indications are difficult to handle, lack specificity, and are not always used.
Quinten Health developed in a partnership with a large French hospital CH Valenciennes a software dedicated to helping hospital pharmacists focus their time on the most critical patients and prescriptions and ease their analysis by providing contextualized information and alerts.
The solution was named PharmIA. It is powered by a combination of Bayesian and deep learning algorithms trained and optimized for the local practice.
The interface allows to display key patients’ characteristics important to be aware of for a hospital pharmacist, as well as the prescriptions to validate. Two algorithms are running to optimize the workflow: one for patients prioritization and another for alerts prioritization.
PharmIA was designed to integrate heterogeneous data sources, such as laboratory values database, literature data on pharmacological and clinical features, drugs information database, patients’ charts, prescription records, as well as Data on local pharmacists/ physicians’ practices.
PharmIA received Big Data for Good award in the end of 2020 and will be commercially available in France in Q2 2021.
 Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015 May;38(5):437–53
 Giardina C, Cutroneo PM, Mocciaro E, Russo GT, Mandraffino G, Basile G, Rapisarda F, Ferrara R, Spina E, Arcoraci V. Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. Front Pharmacol. 2018 Apr 11;9:350.